New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For AKR;MCD;MPEL;SYT;RHHBY;TSM;DST;AET;ATHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
October 20, 2014
07:19 EDTRHHBYIBC Life Sciences to hold a conference
Subscribe for More Information
07:11 EDTRHHBYAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTRHHBYAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:06 EDTRHHBYNewLink announces worldwide license agreement for NLG919 development
Subscribe for More Information
07:04 EDTRHHBYRoche approval would be positive for TESARO, says Jefferies
Subscribe for More Information
06:38 EDTATHNathenahealth price target lowered to $115 from $140 at RBC Capital
Subscribe for More Information
October 19, 2014
18:11 EDTMCDRussia temporarily suspends nine McDonald's restaurants in the country
Subscribe for More Information
16:28 EDTSYTSyngenta faces more lawsuits over genetically engineered corn seeds, WSJ says
Subscribe for More Information
October 17, 2014
10:00 EDTTSMOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AK Steel (AKS) upgraded to Buy from Neutral at Nomura... AMD (AMD) upgraded to Sector Perform from Underperform at Pacific Crest... Atlantic Power (AT) upgraded to Market Perform from Underperform at BMO Capital... Basic Energy (BAS) upgraded to Outperform from Market Perform at Cowen... BorgWarner (BWA) upgraded to Buy from Hold at Deutsche Bank... CA Technologies (CA) upgraded to Overweight from Equal Weight at Barclays... Calumet Specialty Products (CLMT) upgraded to Outperform at Wells Fargo... DHT Holdings (DHT) upgraded to Buy from Hold at Evercore... Exelon (EXC) upgraded to Neutral from Sell at Citigroup... Fifth Third Bancorp (FITB) upgraded to Buy from Neutral at Citigroup... Goldman Sachs (GS) upgraded to Outperform from Market Perform at Keefe Bruyette... Helmerich & Payne (HP) upgraded to Buy from Neutral at UBS... Hilton (HLT) upgraded to Buy from Neutral at SunTrust... Hyatt Hotels (H) upgraded to Outperform from Neutral at Macquarie... IPG Photonics (IPGP) upgraded at Stifel... ITC Holdings (ITC) upgraded to Neutral from Underperform at Credit Suisse... Manpower (MAN) upgraded to Outperform from Market Perform at Avondale... Nabors Industries (NBR) upgraded to Outperform from Market Perform at Cowen... Newpark Resources (NR) upgraded at Cowen... Old Dominion (ODFL) upgraded to Buy from Neutral at Longbow... PDC Energy (PDCE) upgraded at SunTrust... Patterson-UTI (PTEN) upgraded to Buy from Neutral at UBS... PrivateBancorp (PVTB) upgraded to Outperform from Neutral at Macquarie... QLogic (QLGC) upgraded to Buy from Hold at Summit Research... RPC, Inc. (RES) upgraded at Cowen... Sonoco (SON) upgraded to Neutral from Underperform at DA Davidson... Southwestern Energy (SWN) upgraded to Outperform from Market Perform at Raymond James... SunEdison (SUNE) upgraded to Outperform at Cowen... TSMC (TSM) upgraded to Buy from Neutral at Mizuho... Tesco (TESO) upgraded to Outperform from Market Perform at Cowen... UnitedHealth (UNH) upgraded to Outperform from Market Perform at Leerink... Xilinx (XLNX) upgraded to Outperform from Market Perform at Wells Fargo.
09:17 EDTATHNOn The Fly: Pre-market Movers
Subscribe for More Information
08:05 EDTATHNathenahealth reports Q3 adjusted EPS 27c, consensus 27c
athenahealth last night reported Q3 revenue $190.4M, consensus $190.4M. The company reported it grew net new active physicians on athenaCollector, which had 3,420 physicians added, athenaClinicals, which had 2,786 physicians added, and athenaCommunicator, which had 3,846 physicians added, for the three months ended September 30.
07:59 EDTTSMTSMC upgraded to Buy from Neutral at Mizuho
Subscribe for More Information
06:26 EDTTSMTSMC to start production of 16nm process products in 2Q15, DigiTimes says
Subscribe for More Information
October 16, 2014
18:36 EDTATHNOn The Fly: After Hours Movers
Subscribe for More Information
16:07 EDTATHNathenahealth now sees FY14 EPS near high end of range
athenahealth said, "We are not making any changes to the fiscal year 2014 guidance...However, based on our year-to-date performance and current expectations for Q4 2014, we are providing additional insight into our fiscal year 2014 guidance as follows: "We expect GAAP Total Revenue to be at or above the mid-point of the $725M-$755M guidance range. We expect Non-GAAP Adjusted Gross Margin to be close to the mid-point of the 62.5% to 63.5% guidance range. We expect Non-GAAP Adjusted Net Income per Diluted share to be close to the high end of the 98c-$1.10 guidance range."
16:05 EDTATHNathenahealth sees FY14 adjusted EPS 98c-$1.10, consensus $1.09
Subscribe for More Information
14:47 EDTRHHBYRoche in pact with Pharmacyclics to evaluate Imbruvica, Gazyva combo
Subscribe for More Information
14:13 EDTSYTU.S farmers use less fertilizer this autumn as crop prices fade, Reuters says
Subscribe for More Information
13:13 EDTRHHBYRoche considers submitting Ebola test for emergency use approval, WSJ says
Subscribe for More Information
12:54 EDTTSMTSMC upgraded to Overweight from Neutral at HSBC
Subscribe for More Information
11:15 EDTTSMHigh option volume stocks
Subscribe for More Information
09:35 EDTRHHBYDiplomat announces contract to distribute Esbriet
Subscribe for More Information
06:21 EDTMCDMcDonald's rehires former U.S. executive, WSJ reports
Subscribe for More Information
05:58 EDTRHHBYRoche sees FY14 core EPS targeted to grow ahead of sales
Subscribe for More Information
05:56 EDTRHHBYRoche reports 9 month revenue CHF34.76B vs. CHF34.87B last year
Roche CEO Severin Schwan said: “Demand for our products is strong in both divisions and we are well on track to reach our full-year targets. We have had positive news from our product pipeline, including study results for Perjeta in breast cancer and a new combination therapy with Zelboraf in melanoma. The InterMune acquisition has also strengthened our portfolio with a new medicine, Esbriet for idiopathic pulmonary fibrosis, which has now been approved by the FDA. In Diagnostics, growth continues to be driven by the immunodiagnostics business and we have strengthened our molecular diagnostics portfolio with a new generation of testing systems.”
October 15, 2014
15:45 EDTRHHBYFDA approves Esbriet to treat idiopathic pulmonary fibrosis
Subscribe for More Information
13:52 EDTAETAetna will not renew contract for Delaware Medicaid program
Subscribe for More Information
06:28 EDTTSMTSMC lands CPU orders for Apple's next-generation iPad, DigiTimes reports
Subscribe for More Information
October 14, 2014
11:23 EDTRHHBYBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
07:25 EDTTSMTSMC short trade should be revisited, says Susquehanna
Subscribe for More Information
06:29 EDTTSMTSMC and rivals racing to pack computer power in each chip, WSJ says
Subscribe for More Information
October 13, 2014
14:06 EDTMCDMcDonald's to answer questions about food, AP reports
Subscribe for More Information
06:32 EDTMPELMelco Crown shares could rally $10 on Osaka win, says Citigroup
Citigroup estimates shares of Melco Crown could rally up to $10 should the company win a gaming license in Osaka, Japan. Citi expects the gaming bill in Japan to be passed in November, and notes Melco is a major candidate in Osaka. The firm believes the upcoming opening of City of Dreams Manila will be a "game changer" to the Philippines gaming market. It lowered its price target for shares to $43 from $46 and keeps a Buy rating on the name.
October 10, 2014
12:05 EDTSYTUSDA raises U.S. corn production estimate to 14.475B
Subscribe for More Information
October 9, 2014
08:03 EDTAETWellPoint named top Managed Care pick at Jefferies
Subscribe for More Information
October 8, 2014
11:31 EDTRHHBYFDA grants priority review for Genentech's Lucentis
Genentech, a member of the Roche Group (RHHBY), announced that the U.S. FDA has accepted to file the company's supplemental Biologics License Application and granted Priority Review of Lucentis for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7M Americans. The FDA confirmed action date is February 6, 2015. The sBLA was submitted August 7 to address the unmet need for approved ocular medications for the treatment of diabetic retinopathy. If approved by the FDA, Lucentis could be the first eye medicine available for diabetic retinopathy patients. The submission is based on results of the RISE and RIDE Phase III trials in which meaningful improvements in the disease were observed in a clinically significant proportion of diabetic retinopathy patients treated with Lucentis at two years compared to patients treated with sham injections. Benefits of Lucentis treatment were maintained during year three of treatment. The safety in the RISE and RIDE Phase III trials was consistent with previous studies.
10:55 EDTRHHBYLeerink pharmaceuticals analyst holds an analyst/industry conference call
Analysts discuss prospects for drugs that raise HDL cholesterol, effects of CETP mechanism, expectations for REVEAL data and the potential place for CETP inhibitors in a crowded hypersholesterolemia landscape on an Analyst/Industry conference call to be held on October 9 at 11 am.
07:28 EDTMCDMcDonald's brand solid but execution issues remain, says UBS
Subscribe for More Information
07:19 EDTRHHBYCBI to hold a conference
Subscribe for More Information
October 7, 2014
06:19 EDTMCDMcDonald's Japan now sees FY loss of Y17B
McDonald's Japan is forecasting a loss for the full year of Y17B vs. its previous guidance for a Y6B profit, the Financial Times reports. The company, which is 50% owned by McDonald's, sees food supplier problems impacting sales by Y45B.
06:14 EDTTSMSamsung may find difficulty competing with TSMC for Apple chips, DigiTimes says
Subscribe for More Information
October 6, 2014
10:04 EDTMCDOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Abercrombie & Fitch (ANF) downgraded to Neutral from Overweight at Piper Jaffray... Air France-KLM (AFLYY) downgraded to Neutral from Buy at Citigroup... BAE Systems (BAESY) downgraded to Hold from Buy at Societe Generale... Buffalo Wild Wings (BWLD) downgraded to Neutral from Outperform at Wedbush... Church & Dwight (CHD) downgraded to Underweight from Equal Weight at Barclays... Colgate-Palmolive (CL) downgraded to Equal Weight from Overweight at Barclays... Deckers Outdoor (DECK) downgraded to Neutral from Overweight at Piper Jaffray... Delhaize (DEG) downgraded to Hold from Buy at Deutsche Bank... Fortinet (FTNT) downgraded to Equal Weight from Overweight at Morgan Stanley... McDonald's (MCD) downgraded to Equal Weight from Overweight at Morgan Stanley... Midcoast Energy (MEP) downgraded to Neutral from Buy at UBS... Mobileye (MBLY) downgraded to Market Perform from Outperform at Raymond James... Myers Industries (MYE) downgraded to Neutral from Buy at CL King... Nationstar (NSM) downgraded to Underperform from Market Perform at Keefe Bruyette... PTC Therapeutics (PTCT) downgraded to Market Perform at Cowen... PetSmart (PETM) downgraded to Equal Weight from Overweight at Barclays... Qlik Technologies (QLIK) downgraded to Equal Weight from Overweight at Morgan Stanley... Subsea 7 (SUBCY) downgraded to Neutral from Outperform at Exane BNP Paribas... Tekmira (TKMR) downgraded to Market Perform from Outperform at ... XL Group (XL) downgraded to Market Perform from Outperform at FBR Capital... Xoom (XOOM) downgraded to Underweight from Equal-Weight at Evercore.
08:31 EDTMPELMacau reports September casino revenue down 11.7% to 25.56B patacas
Subscribe for More Information
07:09 EDTMCDMcDonald's downgraded to Equal Weight from Overweight at Morgan Stanley
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use